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33 Greater vasopressin-induced vasoconstriction and inferior effects of
nitrovasodilators and milrinone in the radial artery than in the internal
thoracic artery
Wei Wei, MD, Cheng-Qin Yang, MD, Anthony Furnary, MD, and Guo-Wei He, MD, PhD, DSc,
Portland, Ore, and Hong Kong SAR and Wuhan, China
Vasopressin induced a significantly stronger contraction in the RA than in the ITA. Milrinone
caused less relaxation, and pretreatment with milrinone and nitroprusside had little effect in the
RA compared with the ITA in vasopressin-evoked contraction. Nitroglycerin has a potent
relaxation effect but little effect to prevent contraction in both arteries.
41 Impaired mitochondrial response to simulated ischemic injury as a predictor
of the development of atrial fibrillation after cardiac surgery: In vitro study
in human myocardium
Niv Ad, MD, Aviva Schneider, MSc, Igor Khaliulin, PhD, Joseph B. Borman, MD, and
Herzl Schwalb, PhD, Jerusalem, Israel
The pathophysiology of atrial fibrillation, a common complication after cardiac surgery,
remains unclear. Slices of right atrial trabeculae from 50 patients undergoing elective cardiac
surgery were used to assess mitochondrial recovery after simulated ischemia and reoxygenation.
A strong correlation was found between mitochondrial dysfunction after ischemia and
postoperative atrial fibrillation.
46 Myogenic transcranial motor evoked potentials monitoring cannot always
predict neurologic outcome after spinal cord ischemia in rats
Manabu Kakinohana, MD, PhD, Tetsuya Kawabata, MD, Yuji Miyata, MD, and
Kazuhiro Sugahara, MD, PhD, Okinawa, Japan
According to our clinical experience and experimental data, it is suggested that myogenic
transcranial MEP monitoring can be used detect spinal cord ischemia during aortic occlusion
but not always to predict neurologic outcome after spinal cord ischemia and reperfusion in rats.
General Thoracic
Surgery
(GTS)
53 Induction of apoptosis of lung and esophageal cancer cells treated with the
combination of histone deacetylase inhibitor (trichostatin A) and protein
kinase C inhibitor (calphostin C)
Justin B. Maxhimer, BA, Rishindra M. Reddy, MD, Jingtong Zuo, MD, George W. Cole, Jr,
MD, David S. Schrump, MD, FACS, and Dao M. Nguyen, MD, FRCSC, FACS, Bethesda, Md
Through the antiproliferative effect on thoracic cancer cells and the abrogation of the
antiapoptotic factors nuclear factor B and p21, the combination of both a histone deacetylase
inhibitor and a protein kinase C inhibitor might prove useful as a molecular targeted therapy in
late-stage thoracic malignancies.
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